An observational study in Rhabdomyolysis, sponsored by Hannover Medical School. Completed at 1 site in Germany. Open to participants aged Up to 20 Years. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Hannover Medical School · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This retrospective observational cohort study aims to evaluate the clinical characteristics, causes, intensive care management, and outcomes of pediatric patients with rhabdomyolysis admitted to the Pediatric Intensive Care Unit (PICU) at Hannover Medical School between 2007 and 2020. The study uses routinely collected clinical data from medical records without any study-related intervention or additional patient contact.
The primary objective is to identify factors associated with acute kidney injury, mortality, organ failure, and intensive care resource utilization. In addition, the study aims to develop a prognostic score to support early risk stratification of critically ill children with rhabdomyolysis. The findings may improve the understanding of this rare condition and support future clinical decision-making.
Rhabdomyolysis is a rare but potentially life-threatening condition in children characterized by skeletal muscle injury and the release of intracellular components into the circulation. Clinical presentation ranges from mild disease to severe complications, including acute kidney injury, multiple organ dysfunction, and death. Current evidence is limited because most published studies are based on small retrospective case series, and prognostic factors for critically ill pediatric patients remain insufficiently characterized.
This is a single-center, retrospective observational cohort study conducted at the Department of Pediatric Cardiology and Intensive Care Medicine, Hannover Medical School, Germany. The study includes pediatric patients treated in the Pediatric Intensive Care Unit (PICU) between January 1, 2007, and December 31, 2020, with a diagnosis of rhabdomyolysis. Clinical, laboratory, and treatment data are extracted from routinely collected electronic medical records. No study-related interventions are performed, and no additional patient contact takes place.
The study aims to characterize the etiology, clinical course, intensive care resource utilization, and outcomes of pediatric rhabdomyolysis in routine clinical practice. Furthermore, routinely collected clinical and laboratory parameters will be evaluated to develop a prognostic model for early risk stratification of acute kidney injury and mortality in critically ill children. The results are expected to improve the understanding of this rare disease and provide evidence to support future clinical management and research.
40 studies on the registry are indexed under Rhabdomyolysis; 5 are open to participants now.
This study's enrollment of 55 is below the median of 150 across 23 observational studies indexed under Rhabdomyolysis.
Browse Rhabdomyolysis studies →Hannover Medical School is the lead sponsor of 202 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consisted of pediatric patients admitted to the Pediatric Intensive Care Unit (PICU) at Hannover Medical School, Germany, between January 1, 2007, and December 31, 2020. Eligible patients were identified retrospectively from routinely collected electronic hospital records. The cohort represents children treated for rhabdomyolysis at a tertiary care university hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pediatric patients with rhabdomyolysis admitted to the Pediatric Intensive Care Unit (PICU) at Hannover Medical School between January 1, 2007, and December 31, 2020, who fulfilled the predefined eligibility criteria and were included in the final retrospective analysis. Clinical data were obtained from routinely collected medical records.
Acute Kidney Injury (AKI)
Occurrence of acute kidney injury during PICU admission, defined according to the pediatric Risk, Injury, Failure, Loss, End-stage renal disease (pRIFLE) criteria.
Time frame: From PICU admission until PICU discharge ( an average of 18 days)
Mortality
All-cause mortality during PICU admission.
Time frame: From PICU admission until PICU discharge ( an average of 18 days)
Organ Failure
Occurrence of organ failure during the PICU stay based on predefined clinical and laboratory criteria, including respiratory, renal, hepatic, cardiovascular, and multiple organ failure.
Time frame: From PICU admission until PICU discharge ( an average of 18 days)
Duration of invasive mechanical ventilation
Duration of invasive mechanical ventilation during PICU admission.
Time frame: From initiation of invasive mechanical ventilation until discontinuation (up to PICU discharge, in the median 7 days).
Length of PICU stay
Length of stay in the pediatric intensive care unit
Time frame: From PICU admission until PICU discharge ( an average of 18 days)
Requirement for renal replacement therapy
Requirement for renal replacement therapy during PICU admission
Time frame: From PICU admission until PICU discharge ( an average of 18 days)
Peak creatine kinase (CK)
Highest serum creatine kinase (CK) concentration recorded on each PICU day and used for longitudinal statistical analyses.
Time frame: From PICU admission until PICU discharge ( an average of 18 days)
Peak myoglobin
Highest serum myoglobin concentration recorded on each PICU day and used for longitudinal statistical analyses
Time frame: From PICU admission until PICU discharge ( an average of 18 days)
Etiology of rhabdomyolysis
Distribution of the underlying causes of rhabdomyolysis in the study population.
Time frame: Baseline (PICU admission)
Multiple organ involvement
Presence of multiple organ involvement during PICU stay.
Time frame: From PICU admission until PICU discharge ( an average of 18 days)
Comorbidities
Pre-existing medical conditions associated with pediatric rhabdomyolysis.
Time frame: Baseline (PICU admission)
Systemic inflammatory response syndrome (SIRS) or sepsis
Occurrence of systemic inflammatory response syndrome (SIRS) or sepsis according to the International Pediatric Sepsis Consensus Conference criteria.
Time frame: From PICU admission until PICU discharge ( an average of 18 days)
Pediatric Index of Mortality II (PIM II)
Disease severity at PICU admission assessed using the Pediatric Index of Mortality II (PIM II). PIM II estimates the predicted probability of mortality (%) in pediatric intensive care patients. Higher percentages indicate a higher predicted risk of death and greater disease severity.
Time frame: Baseline (PICU admission)
Pediatric Risk of Mortality III (PRISM III)
Disease severity at PICU admission assessed using the Pediatric Risk of Mortality III (PRISM III) score. The PRISM III score ranges from 0 to 74 points, with higher scores indicating greater disease severity and a higher predicted risk of mortality.
Time frame: Baseline (PICU admission)
Plan to share: No — Individual participant data (IPD) will not be shared because this retrospective observational study uses pseudonymized patient data collected during routine clinical care. Data sharing is restricted by institutional policies, ethical requirements, and applicable data protection regulations (including the General Data Protection Regulation [GDPR]).
No publications or documents are linked to this record.
Ran from Jul 2025 to primary completion in Dec 2025, 5 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.